2024
Two mosquito salivary antigens demonstrate promise as biomarkers of recent exposure to P. falciparum infected mosquito bites
Lapidus S, Goheen M, Sy M, Deme A, Ndiaye I, Diedhiou Y, Mbaye A, Hagadorn K, Sene S, Pouye M, Thiam L, Ba A, Guerra N, Mbengue A, Raduwan H, Gagnon J, Vigan-Womas I, Parikh S, Ko A, Ndiaye D, Fikrig E, Chuang Y, Bei A. Two mosquito salivary antigens demonstrate promise as biomarkers of recent exposure to P. falciparum infected mosquito bites. The Journal Of Infectious Diseases 2024, jiae525. PMID: 39475423, DOI: 10.1093/infdis/jiae525.Peer-Reviewed Original ResearchModerate transmission areasMosquito salivary proteinsModerately endemic areaAntibody responseMosquito exposureTransmission seasonP. falciparum infectionMalaria transmission seasonMalaria transmission intensityExposure to infectious mosquitoesMosquito bitesEntomological inoculation rateEndemic areasHuman immune responseInfected mosquito bitesTransmission areasDecline 3 monthsNo antibody responseExposure to infected mosquitoesP. falciparumControl cohortExposure to mosquitoesBead-based assayImmune responseSalivary proteins
2015
The epidemiological impact of HIV antiretroviral therapy on malaria in children
Greenhalgh S, Ndeffo M, Galvani AP, Parikh S. The epidemiological impact of HIV antiretroviral therapy on malaria in children. AIDS 2015, 29: 473-482. PMID: 25486414, PMCID: PMC4391884, DOI: 10.1097/qad.0000000000000550.Peer-Reviewed Original ResearchConceptsHIV protease inhibitorsRecurrent malariaMalaria transmissionAntiretroviral therapyArtemether-lumefantrineAnnual incidenceProtease inhibitorsFirst-line antiretroviral regimenFirst-line antiretroviral therapyArtemether-lumefantrine treatmentHIV-negative childrenFirst-line antimalarialsHIV prevalence settingsHIV antiretroviral therapyRecent clinical trialsHIV prevalence levelsMalaria transmission settingsMalaria transmission intensityAntiretroviral regimenAntimalarial treatmentHIV prevalenceProphylactic effectPrevalence settingsClinical trialsHealth burden